Featured Tickers:

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Nautilus Biotechnology, Inc. before investing.

In this article, we go over a few key elements for understanding Nautilus Biotechnology, Inc.’s stock price such as:

Nautilus Biotechnology, Inc.’s current stock price and volume
Why Nautilus Biotechnology, Inc.’s stock price changed recently
Upgrades and downgrades for NAUT from analysts
NAUT’s stock price momentum as measured by its relative strength

About Nautilus Biotechnology, Inc. (NAUT)

Before we jump into Nautilus Biotechnology, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Want to learn more about Nautilus Biotechnology, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Nautilus Biotechnology, Inc..

Nautilus Biotechnology, Inc.’s Stock Price as of Market Close

As of April 29, 2026, 3:01 PM, CST, Nautilus Biotechnology, Inc.’s stock price was $2.480.

Nautilus Biotechnology, Inc. is down 4.25% from its previous closing price of $2.590.

During the last market session, Nautilus Biotechnology, Inc.’s stock traded between $2.430 and $2.680. Currently, there are approximately 126.37 million shares outstanding for Nautilus Biotechnology, Inc..

Nautilus Biotechnology, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Nautilus Biotechnology, Inc. Stock Price History

Nautilus Biotechnology, Inc.’s (NAUT) price is currently down 36.08% so far this month.

During the month of April, Nautilus Biotechnology, Inc.’s stock price has reached a high of $4.050 and a low of $2.430.

Over the last year, Nautilus Biotechnology, Inc. has hit prices as high as $4.310 and as low as $0.620. Year to date, Nautilus Biotechnology, Inc.’s stock is up 27.18%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Nautilus Biotechnology, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 28, 2026, there were analysts who downgraded Nautilus Biotechnology, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Nautilus Biotechnology, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Nautilus Biotechnology, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Nautilus Biotechnology, Inc. (NAUT) by visiting AAII Stock Evaluator.

Relative Price Strength of Nautilus Biotechnology, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 28, 2026, Nautilus Biotechnology, Inc. has a weighted four-quarter relative price strength of 31.80%, which translates to a Momentum Score of 95 and is considered to be Very Strong.

Want to learn more about how Nautilus Biotechnology, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Nautilus Biotechnology, Inc. Stock Price: Bottom Line

As of April 29, 2026, Nautilus Biotechnology, Inc.’s stock price is $2.480, which is down 4.25% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Nautilus Biotechnology, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.